TriangleNCT00369785 · STUDY IN CONTEXT
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.
In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- trial label
- Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 2
- harms Count
- 2
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- outcome key
- om-0000
- source section id
- NCT00369785-om-0000
- source outcome index
- 0
- endpoint
- Memory as Quantified by HVLT-immediate Recall
- endpoint definition
- Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.
- time origin
- 24 weeks
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Participants with 24 week HVLT data.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- outcome key
- om-0001
- source section id
- NCT00369785-om-0001
- source outcome index
- 1
- endpoint
- Memory as Quantified by the HVLT-discrimination
- endpoint definition
- In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.
- time origin
- 24 weeks
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Number of participants with 24 week memory data
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Arm I - Donepezil
- regimen
- Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
- analyzed count
- 72
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00369785-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- outcome key
- om-0000
- arm key
- OG001
- arm label
- Arm II - Control
- regimen
- Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
- analyzed count
- 73
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00369785-om-0000#groups/OG001
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Arm I - Donepezil
- regimen
- Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
- analyzed count
- 72
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00369785-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- outcome key
- om-0001
- arm key
- OG001
- arm label
- Arm II - Control
- regimen
- Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
- analyzed count
- 73
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00369785-om-0001#groups/OG001
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- harm key
- EG000
- source section id
- NCT00369785-ae
- event group key
- EG000
- event group label
- Arm I - Donepezil
- serious affected
- 12
- serious at risk
- 96
- other affected
- 88
- other at risk
- 96
- frequency threshold
- 5
- collection period
- 24 weeks
- event definition
- Analysis includes everyone with post-treatment AE/toxicity data.
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-central-nervous-system-tumors
- nct id
- NCT00369785
- harm key
- EG001
- source section id
- NCT00369785-ae
- event group key
- EG001
- event group label
- Arm II - Control
- serious affected
- 10
- serious at risk
- 92
- other affected
- 80
- other at risk
- 92
- frequency threshold
- 5
- collection period
- 24 weeks
- event definition
- Analysis includes everyone with post-treatment AE/toxicity data.
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice